Replies to post #183286 on Biotech Values

[DewDiligence]

SNY/NVO/LLY—More on the competitive landscape in diabetes:

http://blogs.wsj.com/pharmalot/2014/10/28/sanofi-diabetes-outlook-signals-an-undisciplined-price-war-may-erupt/

The rumor of a CEO change at SNY appears to have little substance. Viehbacher is not going anywhere, IMO.